Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL-3778 + Peg-IFN in HBeAg-positive CHB
NCT03125213Phase 2Withdrawn
- Sponsor
- Alios BioPharma
- Start
- Sep 2017
- Primary completion
- Feb 2019
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 2, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing Peg-IFN + AL-3778 with Peg-IFN + Placebo (2 arms). Primary endpoint: Mean change in serum HBsAg from baseline at 24 weeks. Planned start Sep 2017; status: withdrawn.
02
Drugs
AL-3778
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03125213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03125213.